Alexandros Ardavanis
Papers
1
Total Citations
25
H-Index
1
About
Dr. Alexandros Ardavanis is a leading figure in medical oncology, with a distinguished career focused on the treatment of genitourinary malignancies, particularly prostate cancer. His most impactful work centers on the real-world efficacy and safety of novel chemotherapeutic agents. Dr. Ardavanis is best known for his pivotal contributions to the pooled analysis of the cabazitaxel compassionate use and early access programmes, a study that provided crucial, large-scale evidence on the drug's performance outside of clinical trials. This landmark research, which has garnered 25 citations, demonstrated the tangible benefits of cabazitaxel for patients with metastatic castration-resistant prostate cancer, validating its role in a heavily pre-treated population. By analyzing data from multiple international centers, his work helped to bridge the gap between controlled trial settings and everyday clinical practice, offering oncologists robust data to guide treatment decisions. Dr. Ardavanis’s dedication to evidence-based oncology and his focus on translating clinical research into real-world patient outcomes have made him a respected authority in the field, influencing therapeutic strategies for advanced prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1